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Cerebral and pulmonary syndromes may develop in unacclimatized individuals shortly after ascent to high altitude resulting in
high altitude illness, which may occur due to extravasation of ﬂuid from intra to extravascular space in the brain, lungs and
peripheral tissues. The objective of the present study was to evaluate the potential of seabuckthorn (SBT) (Hippophae rhamnoides
L.)leafextract(LE)incurtailinghypoxia-inducedtransvascularpermeabilityinthelungsbymeasuringlungwatercontent,leakage
of ﬂuorescein dye into the lungs and further conﬁrmation by quantitation of albumin and protein in the bronchoalveolar lavage
ﬂuid (BALF). Exposure of rats to hypoxia caused a signiﬁcant increase in the transvascular leakage in the lungs. The SBT LE
treated animals showed a signiﬁcant decrease in hypoxia-induced vascular permeability evidenced by decreased water content
and ﬂuorescein leakage in the lungs and decreased albumin and protein content in the BALF. The SBT extract was also able
to signiﬁcantly attenuate hypoxia-induced increase in the levels of proinﬂammatory cytokines and decrease hypoxia-induced
oxidative stress by stabilizing the levels of reduced glutathione and antioxidant enzymes. Pretreatment of the extract also resulted
in a signiﬁcant decrease in the circulatory catecholamines and signiﬁcant increase in the vasorelaxation of the pulmonary arterial
rings as compared with the controls. Further, the extract signiﬁcantly attenuated hypoxia-induced increase in the VEGF levels
in the plasma, BALF (ELISA) and lungs (immunohistochemistry). These observations suggest that SBT LE is able to provide
signiﬁcant protection against hypoxia-induced pulmonary vascular leakage.
1.Introduction
Acute exposure to hypoxia or high altitude induces a
variety of illnesses like acute mountain sickness (AMS),
high altitude pulmonary edema (HAPE) and high altitude
cerebral edema (HACE). Among the high altitude illnesses,
HAPE is the most common fatal manifestation accounting
to most of the deaths [1]. Despite wide recognition of
the clinical features and natural history of high-altitude-
induced disorders, the exact pathogenesis involved remains
speculative. Pulmonary hypertension, increased pulmonary
capillary pressure and enhanced vascular permeability are
the major factors for the development of HAPE [2, 3].
Hypoxia-induced oxidative stress plays a key role for the
development of pulmonary hypertension and vascular leak-
age [4]. Earlier study by Bakonyi and Radak (2004) indicates
that increased generation of reactive oxygen and nitrogen
species may be responsible for hypoxia-induced increase in
vascular permeability, which in turn may increase oxidative
damage of lipids, proteins and DNA, besides decreasing
the activity and eﬀectiveness of the antioxidant enzyme
system [5]. Therefore, supplementation with antioxidants
may provide protection against hypoxia-induced oxidative
stress and thus curtail high-altitude-induced maladies.
The hypoxic stress has also been suggested to elicit
an inﬂammatory response, which chemotactically attracts
alveolar macrophages and neutrophils resulting in release of
inﬂammatory mediators that augment the ﬂuid and albumin
leakage [6].
Vascular permeability factor, also known as VEGF (vas-
cular endothelial growth factor) has been demonstrated to
be involved in the vascular basement-membrane destruction2 Evidence-Based Complementary and Alternative Medicine
and angiogenesis [7–9]. VEGF has been shown to be up-
regulated by hypoxic stress [10, 11] and its overexpression in
the lung induces pulmonary vascular permeability, resulting
in pulmonary edema [12]. In addition, the reactive oxygen
intermediateshavealsobeenimplicatedtoincreasetheVEGF
levels [13, 14].
Seabuckthorn (SBT; Hippophae rhamnoides L., Elaeg-
naceae) is a unique and valuable plant currently being
investigated for its medicinal values all over the world [15–
17]. Studies from our laboratory using immune cells like
rat spleenocytes, murine macrophages (J-774), human lym-
phocytes and C6 glioma cells have demonstrated that SBT
leaves have a signiﬁcant cytoprotective, immunomodulatory
and antioxidant activity [18, 19]. Leaf drugs, which contain
ﬂavanoids, are implicated to increase the wound-healing
eﬀect after chemical burns and plain wounds [20]. The leaf
extract (LE) was also found to provide protection against
chromium-inducedoxidativestress[21],besideshavinganti-
inﬂammatory activity in adjuvant-induced arthritic animals
[22]. The extract was also found to have signiﬁcant antistress
and adaptogenic activity when evaluated in cold-hypoxia-
restrain animal model [23].
It is possible that administration of SBT LE may curtail
hypoxia-induced transvascular permeability and thus may
provide protection against high-altitude-induced maladies.
Therefore, the present study was undertaken to evaluate
eﬃcacy of SBT LE in providing protection against hypoxic
stress in animals exposed to acute hypobaric hypoxia in a
decompression chamber.
2. Methods
2.1. Plant Material. SBT leaves were collected from the hilly
region of Western Himalayas, India, in the month of August
anddriedundershade.Theethanobotanicalidentiﬁcationof
the plant was carried out by the Field Research Laboratory
(Leh, India), where the voucher specimen of the plant
material is preserved in the herbarium.
2.2. Plant Extract Preparation. The alcoholic LE was pre-
paredusing70%ethanolasreportedbySagguetal.[23].The
powdered dry leaves were soaked in 70% ethanol (1:5w/v)
at room temperature (25±1◦C). After 24h, the supernatant
wasdecantedandtheresiduere-soakedinfresh70%ethanol.
The process was repeated four times for complete extraction.
To avoid contamination, clean and sterile conditions were
maintained during the extraction process. The supernatants
were pooled, ﬁltered through muslin cloth and stored
in amber-colored bottles and centrifuged for 15min at
8000g, 4◦C. The supernatant obtained after 15min of
centrifugation was frozen at −20◦C and then lyophilized in a
Heto Lyophilizer (HITOSICC, Heto-Holten A/S, Denmark).
Lyophilized powder of the SBT leaf alcoholic extract was
stored at −20◦C in an airtight glass tube until further use.
The crude yield of the lyophilized extract was determined
gravimetrically by weighing the dried residues obtained out
of known volumes of extract, extracted from known weight
ofdryleavespowder.OnegramofdriedSBTleavesproduced
0.17g of lyophilized SBT ethanolic extract powder.
2.3. Animals. T h es t u d yw a sp e r f o r m e di nﬁ v eb a t c h e so f
male Sprague-Dawley albino rats each weighing 170–200g
maintained at 24±0.5◦Cw i t hf o o da n dw a t e rad libitum.
TheexperimentalprotocolisshowninFigures 1(a)and1(b).
The study was approved by the Institute’s Animal Ethical
Committee and conﬁrms to National guidelines on the care
and use of laboratory animals.
2.3.1. Dose-Response Study. The SBT extracts were diluted
in sterile saline solution and diﬀerent doses (50, 100 and
200mg/kgb.w.) were administered orally using a gastric
canula to determine their eﬃcacy against hypoxia-induced
increase transvascular permeability (Figure 1(a)). Initially,
a dose-response study was carried out in three batches of
animals comprising of six groups of eight animals each
to investigate eﬃcacy of SBT LE in modulating hypoxia-
induced changes in water content and transvascular leakage
in the lungs and albumin and protein levels in the bron-
choalveolar lavage ﬂuid (BALF).
2.3.2. Eﬃcacy of the Eﬀective Dose of Leaf Extract. On the
basis of these studies, an eﬀective dose of SBT LE, which gave
optimal protection against hypoxia-induced transvascular
leakage, was used for further studies (Figure 1(b)).
2.4. Hypoxic Exposure. The diﬀerent groups of animals
received respective preparations asmentioned inFigure 1(a),
orally, 12h prior to exposure to hypoxia, with the help
of a gastric canula, and the normoxic control group was
maintained on saline. Similar method was followed for
administration of dexamethasone (DEXA; 5mg/kg body
weight, bw) after dissolving in 1mL normal saline. DEXA
pretreated animals were taken as positive controls. The
animals were exposed to 9144m in a decompression cham-
ber maintained at 24±0.5◦C (similar to the temperature
at which the animals were normally housed) for 5 hours
for studying the independent eﬀect of hypoxic stress on
transvascular leakage and its modulation by SBT. Airﬂow
into the chamber was maintained at 2L/min.
2.5. Lung Water Content. Wet-to-dry weight ratio was used
as an index of tissue water content. After 5h of hypoxic
exposure the animals were anesthetized using ketamine
(80mg/Kgip) and xylazine (20mg/Kgip), sacriﬁced and
lungs were excised enbloc. The diﬀerent lung lobes were cut,
blot dried and placed on preweighed glass plates. The wet
weightofthetissuewasregisteredimmediately.Thetraywith
the tissue was then baked in a hot air oven at 55◦Cf o r7 2h
to obtain a constant weight. After the dry weight of the tissue
was registered, the water content of the tissue was calculated
as wet weight minus dry weight and expressed as milligrams
of water per milligrams of dry tissue [24].
2.6. Transvascular Leakage. The permeability assays were
performed by the technique of Heike et al. [25] with minor
modiﬁcations using sodium ﬂuorescein (Sigma, USA) dye
extravasation as an indicator of vascular leakage [26]. After
exposure to hypoxia, all the animals received 15mg/kg bw ofEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: (a) Experimental design forthe dose-responsestudyto evaluate theeﬃcacy oftheextract inprotectionagainst hypobaric hypoxia-
induced transvascular leakage in rats. The animals from group (ii) to (vi) were exposed to hypoxia of 9144m for 5h in a decompression
chamber. Eight animals were used in each group. (b) Experimental design for eﬀective dose studies. The animals from group (ii) to (vi) were
exposed to hypoxia of 9144m for 5h in a decompression chamber except VIth batch. Eight animals were used in each group.
sodium ﬂuorescein dye in saline as a bolus through the tail
vein and were re-exposed to hypoxia for additional 30min.
The animals were killed and lungs were taken out for the
measurement of dye leakage after washing with phosphate-
buﬀered saline to remove the excess dye from the pulmonary
vasculature. Lungs were incubated with formamide [27]a n d
the ﬂuorescence was measured after centrifugation at 1500g
for 20min in the supernatant at an excitation wavelength of
485 nm and emission wavelength of 531nm using a Varian
(USA) spectroﬂuorimeter. The values are expressed as rela-
tiveﬂuorescenceunits(rfu)pergramdryweightofthetissue.
2.7.BALF. Animalswereeuthanizedviaanestheticoverdose,
a midline thorax to neck incision was made, the ribs
removed and a tracheal cannula was placed. The lungs
were lavaged in aliquots with sterile phosphate-buﬀered
saline(0.035mL/gbw).Returnedlavageﬂuidwaspooledand
centrifuged at 1000g for 10min at 4◦C for removing cells
and debris and the supernatant was aliquoted and frozen at
−80◦C until assayed.
2.8. Total Protein and Albumin Content in the BALF. Total
protein in the BALF was measured using commercially
available kits obtained from Bangalore Genei, India, whereas
albuminlevelswereestimatedusingELISAkitobtainedfrom
M/S Shibayage (Japan).
2.9. Inﬂammatory Cytokines in the BALF. Inﬂammatory
cytokines (TNF-α, IL-6, IL-10 and MCP-1) in the BALF
of diﬀerent groups of animals were quantiﬁed using ELISA4 Evidence-Based Complementary and Alternative Medicine
kits obtained from M/S BD Biosciences Ltd (USA) as per
the procedures provided by the manufacturer and were
expressed as pg/ml of BALF.
2.10. Oxidative Stress Markers. After exposure to hypoxia
the animal’s thoracic cavity was opened and the pulmonary
vasculature was washed with saline. The lungs were dissected
out and immediately stored at −80◦C until assayed for
oxidative stress parameters.
The lung samples were homogenized with 0.154MKCl
solution in ice cold condition and centrifuged at 3000g
for 15min at 4◦C. The supernatants were analyzed for
free radical [28], malonedialdehyde (MDA; [29]), reduced
glutathione (GSH; [30]), enzymes like glutathione reductase
(GR), glutathione peroxidase (GPx) and superoxide dismu-
tase (SOD) (Randox kits, USA).
2.11. Plasma Collection. Following anesthesia the blood
samples were collected from the abdominal aorta after
opening the abdomen using 20G heparinized vacutainers
(BD). The blood samples were centrifuged immediately at
2500g for 20min at 4◦C. The plasma samples were then
separated and stored at −80◦C until assayed.
2.12. Plasma Catecholamines. The plasma catecholamines
were analyzed in diﬀerent groups of animals using high per-
formance liquid chromatography (HPLC) system (Waters,
USA). The samples for HPLC were prepared by using
Chromsystems kit (USA) [31] and the values were expressed
in terms of pg/mL of plasma.
2.13. BALF and Plasma VEGF. VEGF was quantiﬁed in the
BALF and plasma by ELISA (R&D Systems, Inc., USA) fol-
lowing instructions of the manufacturer. The concentrations
of unknown samples were calculated with reference to the
absorbance of VEGF standards and were expressed in terms
of pg/mL of BALF.
2.14. Immunohistochemical Studies. VEGF expression in
lung was also determined by immunohistochemical studies.
The lungs were inﬂated, and the pulmonary artery was per-
fused with 4% paraformaldehyde. Excised lungs were ﬁxed
in 4% paraformaldehyde overnight at 4◦C and cryosectioned
(Leica, Germany). Frozen sections (60μm) were used for
immunostaining with VEGF-speciﬁc antibodies. Sections
were treated with 0.3% hydrogen peroxide in methanol for
20min, preincubated with 5% goat serum and treated with
anti-VEGF antibody (1:200, Santacruz, USA) for 1h at
37◦C. The sections were then incubated with a biotinylated
goat anti-rabbit secondary antibody, treated with the avidin-
biotin complex (ABC kit, Santacruz, USA), and stained
with diaminobenzidine tetrahydrochloride and hydrogen
peroxide.
2.15. Vascular Reactivity Studies. The vascular reactivity
studies were performed to evaluate vasorelaxant activity
of SBT extracts [32]. After 12h of administration of the
SBT extracts, the animals were anaesthetized, thoracic cavity
Control lung
(a)
Hypoxic lung
(b)
Figure 2: Eﬀect of hypobaric hypoxia on lung morphology. Rats
were exposed to stimulated altitude of 9144m at 24◦Cf o r5h .
was opened and the lungs enbloc with aorta were removed
quickly and placed in cold Kreb’s Ringer solution. The main
pulmonary artery was dissected free and cleaned of fat and
adventitia. The artery was cut into rings of 2-mm long.
Each ring was mounted with two L-shaped stainless steel
hooks in jacketted tissue chambers containing Kreb’s Ringer
solution at 37◦C and gassed with 95% O2 and 5% CO2.
The upper hook of each aortic ring was attached to a force
displacement transducer through a silk suture and changes
in isometric force were recorded on a polygraphic system
(BIOPAC software, USA). Phenylephrine and acetylcholine
were used as standard vasocontractile and vasodilatory
agents. Percentage change in the tension during exposure
to acetylcholine against the tension of phenylephrine was
calculated and compared with various groups for assessing
vascular reactivity.
2.16.StatisticalAnalysis. Allthevaluesareexpressedasmean
± standard deviation (SD). The statistical analysis was done
by using one-way ANOVA followed by Tukey test with the
help of SPSS software. A value of P<. 05 was considered as
statistically signiﬁcant.
3. Results
3.1. Morphological Diﬀerence. Figure 2 shows the morpho-
logical diﬀerence between the lungs of normoxic control and
hypoxia-exposed animals.Evidence-Based Complementary and Alternative Medicine 5
Control Hypoxia SBT LE50 mg SBT LE100 mg SBT LE200 mg
3.0
3.2
3.4
3.6
3.8
4.0
4.2
4.4
4.6
4.8 Lung water content
W
a
t
e
r
c
o
n
t
e
n
t
(
m
g
/
m
g
d
r
y
l
u
n
g
t
i
s
s
u
e
)
∗∗ ∗∗ ∗ ∗# ∗#
DEXA
(a)
Control Hypoxia SBT LE50 mg SBT LE100 mg SBT LE200 mg
r
.
f
.
u
p
e
r
g
r
a
m
d
r
y
t
i
s
s
u
e Fluorescein dye leakage
0
20
40
60
80
100
120
∗∗
∗∗
∗∗##
∗∗## ## ∗
DEXA
(b)
Figure 3: Eﬀect of SBT LE (50, 100 and 200mg/kgbw) on hypobaric hypoxia-induced vascular permeability. Values are mean ± SD (n = 8
per group). Signiﬁcant test between groups were determined by using one-way ANOVA followed by Tukey test. ∗P<. 05 versus Control;
∗∗P<. 01 versus Control; #P<. 05 versus Hypoxia; ##P<. 01 versus Hypoxia.
3.2. Lung Water Content. The lung water content in nor-
moxic control animals varied between 3.10 to 4.19mg/mg
dry tissue with a mean of 3.78±0.39mg/mg dry lung tissue
(Figure 3(a)). The mean value of 4.36± 0.17mg/mg dry
lung tissue in animals exposed to hypoxia was signiﬁcantly
higher (P<. 01) than that of normoxic control animals. The
lung water content in DEXA and SBT LE (100mg/Kgbw)
treated animals was signiﬁcantly lower (P<. 05) than that of
hypoxic control animals, but was higher than the normoxic
control values.
3.3. Transvascular Leakage. The eﬀect of SBT LE on trans-
vascular ﬂuid leakage assessed by quantitation of sodium
ﬂuorescein dye leakage is shown in Figure 3(b).I nc o n -
trol animals the sodium ﬂuorescein dye leakage varied
between 41.46 and 74.55rfu/g lung tissue with a mean
value of 56.81±16.47rfu/g lung tissue. Following expo-
sure to hypoxia the mean ﬂuorescein dye leakage of
98.97±12.78rfu/g lung tissue was signiﬁcantly higher (P<
.01) as compared with normoxic control values. The ani-
mals pretreated with DEXA, which acted as a positive
control, showed a signiﬁcantly lower mean relative ﬂuo-
rescence values (P<. 01) in lungs (71.39 ± 12.14rfu/g
lung tissue) as compared with hypoxic control animals.
Administration of SBT LE (100 and 200mg/Kg bw) showed
a signiﬁcant decrease (72.81±7.78 and 78.03±7.57rfu/g
lung tissue, respectively) (P<. 01) in ﬂuorescein dye
leakage as compared with hypoxic animals. However, the
rfu values in DEXA and SBT LE treated animals were
still signiﬁcantly higher than the normoxic control values.
Since 100mg/Kgbw and 200mg/Kg bw both provided
optimal protection, the lower dose was used for further
studies.
3.4. Total Protein and Albumin Content in BALF. The results
of analysis of BALF protein and albumin contents in
v a r i o u sg r o u p so fa n i m a l se x p o s e dt oh y p o x i cs t r e s sa r e
shown in Figures 4(a) and 4(b). The mean BALF protein
content in animals exposed to hypoxia was signiﬁcantly
higher (165.66±43.21mg/mL) (P<. 01) as compared
with the normoxic control values (93.09±37.95mg/mL).
Pretreatment with DEXA caused a non-signiﬁcant decline
(131.15±34.23mg/mL) (P>. 05) in BALF protein con-
tents as compared with the hypoxic animals. In SBT LE
treated animals (100mg/kgb.w.) the BALF protein contents
were signiﬁcantly lower (P<. 05) (119.11±30.77mg/mL)
as compared with hypoxic animals. In normoxic control
animals the albumin contents in BALF varied between 9.25
and 33.17μg/mL with a mean value of 18.37±8.04μg/mL.
The mean BALF albumin values of 34.67±7.93μg/mL in
animals exposed to hypoxia was signiﬁcantly higher (P<
.01) than that of normoxic control values. Administration
of SBT LE (100mg/kg bw) caused a signiﬁcant decrease
(27.35±4.07μg/mL) (P<. 05) in BALF albumin contents
and the mean value was comparable with DEXA treated
animals (27.44±2.54μg/mL).6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Prevention of extravasation of total protein and albumin by SBT LE (50, 100 and 200mg/kgbw) in rats exposed to simulated
altitude of 9144m for 5h. Values are mean ± SD (n = 8 per group). Signiﬁcant test between groups were determined by using one-way
ANOVA followed by Tukey test. ∗P<. 05 versus Control; ∗∗P<. 01 versus Control; #P<. 05 versus Hypoxia; ##P<. 01 versus Hypoxia.
3.5. Inﬂammatory Cytokines. The cytokines such as TNF-
α, IL-6, IL-10 and MCP-1 were assayed in the BALF of
diﬀerent groups of animals. Hypoxic exposure caused a
signiﬁcant increase (P<. 05) in these proinﬂammatory
cytokines—TNF-α (44%), IL-6 (260%), IL-10 (76%) and
MCP-1 (72%)—in the BALF of animals (Figure 5) than the
normoxic controls. However, this hypoxia-induced increase
in the proinﬂammatory cytokines was markedly reduced
(P<. 05) in the animals pretreated with DEXA—TNF-α
(26%), IL-6 (48%), IL-10 (57%) and MCP-1 (30%)—and
SBT LE—TNF-α (20%), IL-6 (40%), IL-10 (86%) and MCP-
1 (38%).
3.6. Oxidative Stress Markers. Hypoxic exposure caused a
signiﬁcant increase (P<. 05) in the oxidative stress markers
like free radicals (87%) and MDA (21%) and marked
decrease in GSH (19%) levels in the lung homogenates than
the normoxic controls (Table 1,P a n e lA ) .T h ep r e t r e a t m e n t
of animals with SBT LE signiﬁcantly attenuated (P<. 05) the
freeradical(24%)andMDA(24%)generationandincreased
the GSH (28%) levels as compared with the hypoxic animals.
Table 1 (Panel B) shows the level of antioxidant enzyme
levels such as GR, GPx and SOD analyzed in the lung
homogenates of animals of diﬀerent groups. There was
a signiﬁcant decrease (P<. 05) in the GR (14%) and
GPx (17%) enzyme levels on exposure to hypoxic insult as
compared with the normoxic controls. The pretreatment of
animals with LE of SBT caused a marked increased in GR
(17%) and GPx (16%) levels as compared with the hypoxic
animals.
3.7. Plasma Catecholamines. Table 2 represents the circula-
tory levels of catecholamines in diﬀerent groups of animals.
In comparison with the controls, the plasma epinephrine,
norepinephrine and dopamine levels were signiﬁcantly
higher when the animals were exposed to hypoxia. The
administration of DEXA showed a signiﬁcant decline (P<
.05) in the plasma catecholamine levels than the animals
exposed to hypoxia. Although, the SBT LE pretreatment
showed a marked decline (P>. 05) in majority of the plasma
catecholamine levels than the hypoxic animals, the mean
value was not comparable with the DEXA treated animals.
3.8.VEGFLevel inBALFandPlasma. Incontrolanimals, the
BALF VEGF levels varied between 91.14 and 257.22pg/mL
with a mean value of 182.78±62.48pg/mL (Figure 6(a)). In
animals exposed to hypoxia, the mean BALF VEGF value
of 289.04 ± 66.38 pg/ml was signiﬁcantly higher (P<
0.05) than the control values. The plasma VEGF levelsEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: BALF inﬂammatory cytokines in SBT LE (100mg/kgbw) treated animals exposed to simulated high altitude of 9144m for 5h.
Values are mean ± SD (n = 8 per group). Signiﬁcant test between groups were determined by using one-way ANOVA followed by Tukey test.
∗P<. 05 versus Control; ∗∗P<. 01 versus Control; #P<. 05 versus Hypoxia; ##P<. 01 versus Hypoxia. TNF-α, tumor necrosis factor-alpha;
IL-6, Interleukin-6; IL-10, Interleukin-10; MCP-1, Macrophage chemoacttractant protein-1.
Table 1: Eﬀect of SBT LE (100mg/kgbw) on changes in hypobaric hypoxia-induced oxidative stress markers and antioxidant enzymes in
lungs of diﬀerent groups of animals.
Control Hypoxia DEXA 5mg/kgbw SBT LE 100mg/kgbw
Panel A
Rfu 4.03 ±0.99 7.57 ±1.79
∗∗ 6.63 ±1.52
∗∗ 5.76 ±0.64
∗#
MDA (n mol/g) 170.6 ±19.8 211.8 ±13.0
∗∗ 174.1 ±25.5# 159.4 ±19.5##
Panel B
GSH (ng/g) 19.2 ±1.61 5 .4 ±3.3
∗ 17.5 ±4.91 9 .7 ±4.1#
GR (U/L) 190.59 ±18.12 162.57 ±10.02
∗∗ 185.75 ±25.05 190.60 ±5.01##
GPx (U/L) 781.38 ±69.61 644.55 ±53.50
∗ 663.14 ±32.41
∗ 744.92 ±38.17#
SOD (U/mL) 4.16 ±0.30 3.96 ±0.31 3.97 ± 0.35 4.07 ±0.17
Values are expressed as mean ± SD (n = 8 per group). Signiﬁcant test between groups were determined by using one-way ANOVA followed by Tukey test.
∗P<. 05 versus Control; ∗∗P<. 01 versus Control; #P<. 05 versus hypoxia; ##P<. 01 versus hypoxia.
Table 2: Circulating levels of epinephrine, norepinephrine and dopamine in animals pretreated with DEXA, SBT LE (100mg/kgbw)
following exposure to hypoxia of 9144m for 5h.
Control Hypoxia DEXA 5mg/kgbw SBT SL 100mg/kgbw
Epinephrine (pg/mL) 122.07 ±90.31 956.92 ±884.12
∗∗ 406.96 ±361.17
∗# 739.46 ±490.22
∗∗
Norepinephrine (pg/mL) 103.23 ±67.74 1201 ±880.14
∗∗ 296.30 ±168.71
∗∗## 781.85 ±528.38
∗∗#
Dopamine (pg/mL) 34.46 ±28.45 1508.44 ±716.25
∗ 138.84 ±406.46## 460.15 ±348.58
∗#
Values are expressed as mean ± SD (n = 16 per group). Signiﬁcant test between groups were determined by using one-way ANOVA followed by Tukey test.
∗P<. 05 versus Control; ∗∗P<. 01 versus Control; #P<. 05 versus hypoxia; ##P<. 01 versus hypoxia.8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: BALF and plasma VEGF levels in control and hypoxic rats pretreated with SBT LE (100mg/kgbw). Values are mean ± SD (n = 8
per group). Signiﬁcant test between groups were determined by using one-way ANOVA followed by Tukey test. ∗P<. 05 versus Control;
∗∗P<. 01 versus Control.
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Figure 7: Reduction of VEGF immunohistochemical staining after pretreatment with DEXA and SBT LE (100mg/kgbw) in rats exposed to
simulated high altitude of 9144m for 5h. Minimal VEGF immunostaining was evident in lung parenchyma in control animals in contrast
to abundant VEGF immunostaning in the hypoxic group. Pretreatment with DEXA, SBT LE reduced VEGF staining and maintained the
capillary integrity. The photographs are representative of three animals examined under each condition. Original magniﬁcation: ×200.
varied between 0 and 40.90pg/mL with a mean value of
7.73±13.98pg/mL. In the animals exposed to hypoxia, the
mean value of 64.33±54.89pg/mL was signiﬁcantly higher
(P<. 05) than the control values. In SBT LE pretreated
animals, although there was a decline in plasma VEGF levels
than the animals exposed to hypoxia, the values were not
statistically signiﬁcant (P>. 05) (Figure 6(b)).
3.9.LungVEGFImmunohistochemistry. VEGFimmunoreac-
tivity was detected throughout the lung parenchyma after
5h of hypoxic exposure (Figure 7). As evident from the
Figure 7 low degree of staining was observed in the lungs of
control animals. In contrast, higher VEGF immunoreactivity
was present in alveolar epithelial cells, vascular structures,
as well as in large airways of hypoxic animals. The VEGFEvidence-Based Complementary and Alternative Medicine 9
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Figure 8: Eﬀect of SBT LE on vascular reactivity. The animals were pretreated with DEXA and SBT LE (100mg/kgbw). Vascular reactivity
response in control and treated groups. Signiﬁcant test between groups were determined by using one-way ANOVA followed by Tukey test.
∗P<. 05 versus control. Ach, acetylcholine.
immunostaining in lung parenchyma of the animals pre-
treated with DEXA, SBT LE was markedly decreased as
compared with the group exposed to hypoxia only.
3.10. Vascular Reactivity Studies. Figure 8 shows the vascular
reactivity of pulmonary arterial segments of animals in dif-
ferentgroups.Addition ofphenylephrine106 Mcausedasig-
niﬁcant vasoconstriction that could be relieved by addition
of acetylcholine in a dose-dependent manner. In the control
animals, the optimum acetylcholine concentration depen-
dent relaxation was observed at 105 M (21.30±9.41%).
On pretreatment of animals with SBT LE, a signiﬁcant
increase (P<. 05) in acetylcholine concentration dependent
relaxation (28.48±5.86%) was observed in comparison with
the control animals which was 25% higher than the control
values.
4. Discussion
The results from the present study suggest that SBT LE is
able to enhance hypoxic tolerance in experimental animals
subjected to simulated hypobaric hypoxic stress. Adminis-
tration of SBT LE caused a marked decline in transvascular
ﬂuid leakage into the lungs besides curtailing leakage of
proteins and albumin into the alveoli and decreasing the
proinﬂammatory markers in the lung.
HAPE has been demonstrated to occur due to increased
leakage of vascular components into the lungs as a result
of hypoxic insult. Many previous studies have shown that
HAPEisassociatedwithincreaseinleakageofﬂuids,proteins
likealbuminandothervascularcomponents[2,33–35]fr o m
the capillaries into the alveolar space.
Our observations on increase in lung water content
following exposure to hypoxia are in agreement with the
observations of earlier investigators [34, 36]. The increase in
lungwatercontentappearstobeduetoleakageofﬂuidsfrom
intravascular to extravascular ﬂuid compartment [37, 38].
However, when SBT pretreated animals were exposed to
hypoxia, a signiﬁcant decline in lung water content was
observed as compared with hypoxic controls, which was
at par with DEXA treated animals. Besides measuring the
lung water content, the transvascular ﬂuid leakage was also
monitored using sodium ﬂuorescein dye as an indicator.
Animals exposed to hypoxia showed a signiﬁcant increase in
ﬂuorescein dye leakage as compared with normoxic controls.
This observation coincides with the ﬁndings of Heike et al.
[25] who have demonstrated an increase in ﬂuorescein dye
leakageinthebrainbloodvessels,asanindicatorofenhanced
vascular permeability in mice exposed to hypoxic stress. The
observation that SBT LE was able to curtail the dye leakage
followingexposuretohypoxiasuggeststhattheextractisable
to maintain alveolar arterial capillary membrane integrity.
Many earlier studies have reported that HAPE is associ-
ated with the leakage of highly concentrated proteinaeous
ﬂuid [36, 38, 39] speciﬁcally albumin [40–43] into the
lung from the pulmonary vasculature. The results of our
study also demonstrated a marked increase in total protein
and albumin in the BALF of animals exposed to hypoxic
stress. However, administration of SBT LE signiﬁcantly
curtailed hypoxia-induced increase in total protein and
albumin leakage suggesting that the LE besides decreasing10 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Mechanism of prevention of SBT LE against hypoxia-indused vascular leakage. The cross indicates that SBT LE is able to inhibit
the hypoxia-induced pathophysiological process, thereby inhibiting the capillary leakage.
ﬂuid leakage is also able to inhibit leakage of proteins into
the alveoli.
To evaluate the role of lung inﬂammation in setting up
the pathogenesis of HAPE under decreased alveolar oxygen
levels, proinﬂammatory cytokines such as TNF-α,I L - 6 ,I L -
10 and MCP-1 were also measured in the BALF of animals
subjected to hypoxic stress since all these cytokines have
been suggested to be associated with airway inﬂammation in
HAPE patients [40]. Hypoxic exposure caused a signiﬁcant
increase in the inﬂammatory interleukins (TNF-α,I L - 6 ,I L -
10 and MCP-1) as compared with the normoxic controls.
However, the animals pretreated with SBT extract showed
a marked decrease in these interleukins as compared with
hypoxic controls suggesting that hypoxia-induced alveolar
inﬂammation can be prevented signiﬁcantly by SBT LE.
Besides curtailing hypoxia-induced alveolar inﬂamma-
tion SBT LE also caused a marked reduction in alveolar
oxidative stress. The reactive oxygen and nitrogen species
have been implicated in the causation of AMS, HAPE and
HACE [5, 44–46]. Free radicals are implicated to damage
biomembranes, thereby compromising cell integrity and
function[47].Besidesincreasingpulmonaryarterialpressure
[4], the free radical production under hypoxic environment
maycauseoxidativeinjuryoftheendothelium[48],resulting
in increased pulmonary capillary permeability. Hence, the
oxidativestressmarkers(freeradical,GSH,MDA,SOD,GPx,
GR) were measured in the lung homogenates of diﬀerent
groups of animals. Hypoxic exposure caused a signiﬁcant
increase in the levels of free radical and MDA and decreased
the antioxidant enzyme system. Pretreatment of animals
with SBT extracts about 12h prior to hypoxic exposure
caused a marked reduction in free radical and MDA levels
and increased GSH, SOD, GPx and GR, thereby providing
a signiﬁcant protection against hypoxia-induced oxidative
damage.
Acute hypoxemia has been shown to enhance sym-
pathetic nerve activity, release of catecholamines, regional
vasoconstriction and heart rate in spontaneously breathing
and anaesthetized mammals [49, 50]. The catecholamines
have been also demonstrated to augment the production of
free radicals by auto-oxidation of monoamines to produce
superoxide and hydrogen peroxide radicals under hypoxic
stress [50, 51]. Therefore, the circulatory levels of cate-
cholamines were estimated in animals exposed to hypoxic
stress.Theepinephrine,norepinephrineanddopaminelevels
were markedly increased in animals following exposure to
hypoxia. However, this rise in plasma epinephrine, nore-
pinephrine and dopamine in animals treated with SBT LE
was signiﬁcantly lower than in the untreated animals.
VEGF is a potent mediator of capillary leak if it gains
access to its receptors on the capillary endothelium and
may be inﬂuenced by hypoxic stress. Over expression of
VEGF has been demonstrated to induce formation of
fenestrations (small pores) and the thin endothelial cell
cytoplasm may allow leak of solutes [53]. Therefore, VEGF
e s t i m a t i o nw a sc a r r i e do u ti np l a s m aa sw e l la si nB A L FEvidence-Based Complementary and Alternative Medicine 11
of animals after exposure to hypoxic stress. In the BALF
of the hypoxic animals, the VEGF levels were found to
be 58% higher than the controls. However, pretreatment
with SBT LE inhibited hypoxia-induced VEGF increase in
the BALF by 18% as compared with the hypoxic group.
In plasma, the VEGF levels of control animals were almost
undetectable. There was a marked increase in circulatory
levels of VEGF following exposure to hypoxia. However,
this increase in plasma VEGF was attenuated when the
animalswerepretreated withSBTLE(57%).Althoughblood
levels do not generally reﬂect the pulmonary concentrations,
our immunohistochemistry results conﬁrmed the abundant
presence of VEGF peptide in the lung parenchyma in the
setting of hypoxia. The staining of VEGF was very intense in
the alveolar parenchyma in the animals exposed to hypoxic
stress than the controls. However, a marked reduction in the
immunohistochemical staining was observed when the ani-
mals were pretreated with SBT LE as compared with hypoxic
controls.
The vascular reactivity studies were carried out in the
aortic rings of diﬀerent groups of animals to evaluate
the vasorelaxant activity of SBT LE. As compared with
controls, the SBT LE pretreated group showed a signiﬁcant
vasorelaxationresponse. ThevasorelaxantactivityoftheSBT
leaf may be due to the presence of ß-Amyrinoleylalcohol
acid, which has been reported to dilate the cardiac and
cerebral vessels, thereby facilitating blood circulation and
lowering of the blood pressure [54]. Since hypoxia-induced
alveolar vasoconstriction has been suggested as an important
contributory factor in the pathogenesis of HAPE, the
LE may counteract vasocontractile eﬀect of the hypoxic
stress.
Hencefromtheaboveobservations,theSBTLEprovided
signiﬁcant protection against hypoxia-induced transvascu-
lar permeability by reducing alveolar oxidative stress and
inﬂammation. The extract also attenuated the hypoxia-
induced increase in VEGF and catecholamine levels, which
in turn was responsible for a decrease in transvascular
ﬂuid leakage in the lungs (Figure 9). The main antioxidant
components of leaves are ﬂavonoids, which comprises of
leucoanthocyanidins, quercetin, isorhamnetin, epicatechin
and ﬂavonols [55]. Therefore, it is possible that SBT LE
by enhancing the endogenous antioxidant defense system
and by curtailing the oxidative stress and inﬂammatory
response, maymaintain the alveolarmembraneintegrity and
thus prevent hypoxia-induced increase in alveolar vascular
permeability.
In conclusion, these results suggest that HAPE whose
pathogenesis is a multifactorial phenomenon, can be pre-
vented signiﬁcantly by the diverse activities of bioactive
moleculespresentinSBTLE,whichcanbedevelopedasfood
supplement and/or nutrceutical to enhance tolerance to the
hypoxic environment.
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